| Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. Co.'s primary program is the development of Endoxifen, an active metabolite of tamoxifen which is a U.S. Food and Drug Administration-approved drug, to treat and prevent breast cancer in high risk women. Co.'s primary goal is to develop its proprietary oral Endoxifen to reduce mammographic breast density. Co. is also developing oral Endoxifen to potentially treat breast cancer in the window of opportunity between diagnosis of breast cancer and surgery. We show 12 historical shares outstanding datapoints in our ATOS shares outstanding history coverage, used to compute ATOS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATOS market cap history over the course of time is important for investors
interested in comparing ATOS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATOS versus a peer is one thing; comparing
ATOS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATOS can fluctuate over the course of history.
With this page we aim to empower investors researching ATOS by allowing them to research the ATOS market cap history.